2022
DOI: 10.1186/s12951-022-01413-w
|View full text |Cite
|
Sign up to set email alerts
|

NOX4 blockade suppresses titanium nanoparticle-induced bone destruction via activation of the Nrf2 signaling pathway

Abstract: Periprosthetic osteolysis (PPO) triggered by wear particles is the most severe complication of total joint replacement (TJR) surgeries, representing the major cause of implant failure, which is public health concern worldwide. Previous studies have confirmed the specialized role of osteoclast-induced progressive bone destruction in the progression of PPO. Additionally, the reactive oxygen species (ROS) induced by wear particles can promote excessive osteoclastogenesis and bone resorption. Nicotinamide adenine … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 61 publications
0
4
0
Order By: Relevance
“…The sizes of the Ti nanoparticles ranged from 24.51-233.58 nm. These particles proved to be effective in our previous study [25].…”
Section: Detection and Preparation Of Ti Nanoparticlementioning
confidence: 59%
“…The sizes of the Ti nanoparticles ranged from 24.51-233.58 nm. These particles proved to be effective in our previous study [25].…”
Section: Detection and Preparation Of Ti Nanoparticlementioning
confidence: 59%
“…The sizes of the Ti particles ranged from 24.51 to 233.58 nm. These particles proved to be effective in our previous study [ 42 ].…”
Section: Methodsmentioning
confidence: 92%
“…Wear particles induce ROS-mediated immune responses ( 24 ) and are crucial for RANKL-induced osteoclast differentiation ( 38 ). Elevated ROS levels decrease Nrf2 expression, thereby contributing to increased Nfatc1 expression during osteoclast formation ( 39 , 40 ). Accordingly, ROS signaling is indicated to be a suitable target for the pharmacological treatment of bone loss ( 30 ).…”
Section: Discussionmentioning
confidence: 99%